MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.75
+0.66
+7.26%
After Hours: 9.68 -0.07 -0.72% 19:59 01/15 EST
OPEN
9.10
PREV CLOSE
9.09
HIGH
9.97
LOW
9.10
VOLUME
388.57K
TURNOVER
--
52 WEEK HIGH
18.26
52 WEEK LOW
4.510
MARKET CAP
56.22M
P/E (TTM)
-1.1135
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Achieve Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced that John Bencich, Chief Executive Officer, will present at the H.C. Wainwright BioConnect Conference being held virtually January 11-14, 2021.
ACCESSWIRE · 01/07 10:36
Achieve Life Sciences to Present at H.C. Wainwright Virtual BioConnect Conference
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / January 7, 2021 / Achieve Life Sciences, Inc.
ACCESSWIRE · 01/07 10:30
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
and , /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten public offering of 2,472,500 shares of its common stock at a public offering price of , for total  gross proceeds of , prior to deducting underwriting discounts and commissions and estimated offering expenses. This includes the full exercise of the underwriter's over-allotment option to purchase an additional 322,500 shares of common stock.
PR Newswire - PRF · 12/07/2020 21:05
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
PR Newswire · 12/07/2020 21:05
Achieve Life Sciences, Inc. Announces Closing of $17.3 Million Underwritten Public Offering, Including Full Exercise of Overallotment Option
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the closing of an underwritten publ...
PR Newswire · 12/07/2020 21:05
Achieve Life Sciences Announces Pricing Of $15M Offering Of 2.15M Shares At $7/Share
Achieve Life Sciences Announces Pricing of $15 Million Public Offering SEATTLE and VANCOUVER, B.C., Dec. 3, 2020 /PRNewswire/ -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage
Benzinga · 12/03/2020 13:10
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
and , /PRNewswire/ -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced the pricing of an underwritten public offering of 2,150,000 shares of its common stock at a price to the public of per share. The aggregate gross proceeds from this offering are expected to be approximately , before deducting underwriting discounts and commissions and other offering expenses payable by Achieve. Achieve has also granted the underwriters a 30-day option to purchase up to an additional 322,500 shares of common stock in connection with the public offering.  All of the securities are being offered by Achieve. The offering is expected to close on or about , subject to the satisfaction of customary closing conditions. 
PR Newswire - PRF · 12/03/2020 13:00
Achieve Life Sciences Announces Pricing of $15 Million Public Offering
PR Newswire · 12/03/2020 13:00
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACHV stock price target is 45.00 with a high estimate of 100.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 39
Institutional Holdings: 1.11M
% Owned: 19.32%
Shares Outstanding: 5.77M
TypeInstitutionsShares
Increased
3
117.44K
New
16
-112.34K
Decreased
3
2.57K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.21%
Key Executives
Chairman/Executive Director
Richard Stewart
President
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Director
Scott Cormack
Independent Director
Donald Joseph
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
Independent Director
H. Stewart Parker
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.